{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/polycythaemia-erythrocytosis/management/management/","result":{"pageContext":{"chapter":{"id":"46e0c8f9-21ea-5ab6-a9ed-601bfd74f61c","slug":"management","fullItemName":"Scenario: Management","depth":2,"htmlHeader":"<!-- begin field 763e29c8-3cff-4172-8a98-ea0050bdab66 --><h2>Scenario: Management of polycythaemia/erythrocytosis</h2><!-- end field 763e29c8-3cff-4172-8a98-ea0050bdab66 -->","summary":"Covers the primary care management of polycythaemia/erythrocytosis and provides information on the secondary care investigations and treatment that can be expected following referral.","htmlStringContent":"<!-- begin item c4696a0e-f345-430a-8475-89dad3ce3e27 --><!-- begin field d45e3d7b-1d63-45f0-bec2-acbc015866cb --><p>From age 18 years onwards.</p><!-- end field d45e3d7b-1d63-45f0-bec2-acbc015866cb --><!-- end item c4696a0e-f345-430a-8475-89dad3ce3e27 -->","topic":{"id":"fa6be70e-4297-5c9a-b3cd-9583f15e3111","topicId":"fd54e0c5-4fe5-450d-9784-91b5e47c8754","topicName":"Polycythaemia/erythrocytosis","slug":"polycythaemia-erythrocytosis","lastRevised":"Last revised in September 2020","chapters":[{"id":"695f9a30-5f1b-5c8c-b771-0c9194a05dbe","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"7dd62db3-3d83-5397-87de-2926d3fd4a22","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"fe394ca3-8f2b-5b5b-97cf-db1e470cb964","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"63325ec1-5a65-517d-b0aa-d0e73bebbfca","slug":"changes","fullItemName":"Changes"},{"id":"d7d77004-b1a3-5b51-b127-56e529c85135","slug":"update","fullItemName":"Update"}]},{"id":"43b989c9-04a9-5339-b325-9131b5be941b","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"dd6ff7fe-7c84-572b-8476-d38ff3f127b6","slug":"goals","fullItemName":"Goals"},{"id":"b5793099-ce5d-5936-b15e-74b920fb9648","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ff345f15-3d9a-5bde-8daf-a7935cbaf03a","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"f3fd1887-7475-5781-8fbf-fe5899828386","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"e0f239a5-035b-518f-b47b-e9c2ba32eac2","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"37e2c554-6ed2-5a18-aaeb-04351cd1273a","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d7d4ea60-5030-5464-990d-fa4317fe399e","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"8bd9e0dc-e10a-53f3-8c7b-9385de985b19","slug":"definition","fullItemName":"Definition"},{"id":"82d6faa0-d4d9-5b16-8749-a562fb4b9c4a","slug":"prevalence","fullItemName":"Prevalence"},{"id":"492c4d23-53a9-5d43-ac41-bbf40de526d8","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"69cfa130-4762-5abc-9ddf-36ad93773d75","slug":"complications-prognosis","fullItemName":"Complications and prognosis"}]},{"id":"5c705230-ec55-58d0-83c7-3782f3fff5c0","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"09648da8-6172-59c1-aba9-f14b74a1e6a9","slug":"diagnosis","fullItemName":"Diagnosis"}]},{"id":"089b1374-e8b4-5137-a954-4b1f90ee4a45","fullItemName":"Management","slug":"management","subChapters":[{"id":"46e0c8f9-21ea-5ab6-a9ed-601bfd74f61c","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"7cc68f5a-878e-564c-97aa-93d8d958e493","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"155ff0de-0d61-5d85-8d21-e9e9cee45889","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"8c94b288-e2c4-56e8-8f74-a64ecc4a7198","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"f2439e91-a3f2-5e18-a9d5-5e82382bce20","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"98ba96ac-671e-5fdc-bf1e-b66cf9498201","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"da8ecf5e-0c5a-5650-b332-70e4aba2d39b","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"6b7583d4-db4f-5b06-a69f-04a4f75b8cbb","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"c2217823-75aa-544d-ab7d-25d4d3f09c5c","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"089b1374-e8b4-5137-a954-4b1f90ee4a45","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"c06df325-0e11-5945-9ada-8252858f6c9b","slug":"management-of-erythrocytosis-polycythaemia","fullItemName":"Management of erythrocytosis/polycythaemia","depth":3,"htmlHeader":"<!-- begin field cd65e3dd-3496-4963-a43e-b4b7b66a7f3f --><h3>How should I manage a person with erythrocytosis/polycythaemia?</h3><!-- end field cd65e3dd-3496-4963-a43e-b4b7b66a7f3f -->","summary":null,"htmlStringContent":"<!-- begin item 94a22469-6340-4789-9080-0a23acb967c5 --><!-- begin field ca810c2d-3b72-4e89-b35d-dec2e2479a36 --><ul><li><strong>If polycythaemia vera is suspected, and/or the person is experiencing symptoms of hyperviscosity, refer urgently to a haematologist for <a class=\"topic-reference internal-reference\" href=\"/topics/polycythaemia-erythrocytosis/management/management/#secondary-care-treatment-of-polycythaemia-vera\">treatment</a>.</strong></li><li><strong>Referral is also indicated for people testing negative for the <em>JAK2</em> V617F mutation, with other features suggestive of a myeloproliferative disease</strong> such as high platelets and/or white count, enlarged spleen, family history of myeloproliferative disease, previous history of thrombosis, altered erythropoietin levels. Tests for uncommon <em>JAK2</em> exon 12 mutations will be carried out to definitively confirm/refute polycythaemia vera. Tests for other rare congenital/familial polycythaemias may also be indicated.</li><li><strong>Specialist advice should also be sought if there is any uncertainty regarding the diagnosis.</strong></li><li><strong>If apparent erythrocytosis is suspected:</strong><ul><li>Address factors that may lead to reduced plasma volume, including smoking, alcohol consumption, obesity, and hypertension For further information, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/smoking-cessation/\">Smoking cessation</a>, <a class=\"topic-reference external-reference\" href=\"/topics/alcohol-problem-drinking/\">Alcohol - problem drinking</a>, <a class=\"topic-reference external-reference\" href=\"/topics/obesity/\">Obesity</a>, and <a class=\"topic-reference external-reference\" href=\"/topics/hypertension-not-diabetic/\">Hypertension - not diabetic</a>.</li><li>If the person is taking a thiazide diuretic, consider switching to an alternative anti-hypertensive agent. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/hypertension-not-diabetic/\">Hypertension - not diabetic</a>.</li><li>Advise that the person avoids use of testosterone supplements and anabolic steroids (if applicable).<ul><li>Blood sampling should be repeated two months after these measures are implemented, to determine whether the haematocrit has normalised. If not, further tests should be carried out to rule out secondary erythrocytosis/polycythaemia vera.</li><li>People with confirmed apparent erythrocytosis should be offered a blood test every 3-6 months in primary care, and if their haematocrit is greater than 0.45 on two consecutive occasions, the person should be referred to haematology to commence a venesection programme.</li></ul></li></ul></li><li><strong>If</strong><strong> secondary erythrocytosis is suspected, </strong><strong>refer to an appropriate specialist to ensure optimal management of the underlying cause:</strong><ul><li>Refer people with elevated erythropoietin levels without a chronic hypoxic disorder to haematology to exclude an erythropoietin-secreting malignancy or other rare causes of secondary polycythaemia.</li><li>Refer people with suspected cyanotic heart disease to a cardiologist.</li><li>Refer people with suspected hypoxic lung disease to a respiratory physician if necessary, or manage in primary care if appropriate. Smoking cessation should be encouraged where applicable. For more information, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/\">Chronic obstructive pulmonary disease</a>, and <a class=\"topic-reference external-reference\" href=\"/topics/smoking-cessation/\">Smoking cessation</a>.</li><li>Refer people with suspected sleep apnoea to a sleep clinic. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/obstructive-sleep-apnoea-syndrome/\">Obstructive sleep apnoea syndrome</a>.</li><li>Refer people with suspected renal disease to renal services.<ul><li>Note: blood sampling should be repeated two months after any measures have been implemented to improve hypoxia (such as smoking cessation, supplemental oxygen, or continuous positive airway pressure [CPAP]) or to treat any other potentially causative conditions. If the haematocrit has not normalised, further <a class=\"topic-reference internal-reference\" href=\"/topics/polycythaemia-erythrocytosis/diagnosis/\">investigation</a> is necessary and a primary haematological disorder should be considered.</li><li>People with confirmed secondary erythrocytosis should receive regular blood tests to monitor haematocrit levels. The target haematocrit is usually 0.54. Where this monitoring occurs in primary care, referral for venesection should be considered for people with raised haematocrit.</li></ul></li></ul></li><li><strong>For all people with polycythemia/erythrocytosis, m</strong><strong>anage cardiovascular disease risk factors, </strong>including hyperlipidaemia, diabetes, hypertension, and smoking. For further information, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/cvd-risk-assessment-management/\">CVD risk assessment and management</a>, <a class=\"topic-reference external-reference\" href=\"/topics/diabetes-type-2/\">Diabetes - type 2</a>, <a class=\"topic-reference external-reference\" href=\"/topics/hypertension-not-diabetic/\">Hypertension - not diabetic</a>, and <a class=\"topic-reference external-reference\" href=\"/topics/smoking-cessation/\">Smoking cessation</a>.<ul><li><strong>Note:</strong> iron replacement should be used judiciously in people with erythrocytosis.</li></ul></li><li><strong>People with polycythaemia vera require annual follow-up</strong> which can be done in primary care to detect the 2-8% who will transform myelofibrosis or the 1-3% who will transform to acute myeloid leukaemia.<ul><li>Features suggestive of myelofibrosis include anaemia or sustained loss of requirement for either venesection (in the absence of cytoreductive therapy) or cytoreductive treatment for erythrocytosis, a leukoerythroblastic peripheral blood picture, increasing splenomegaly (defined as either an increase in palpable splenomegaly of ≥5 cm [distance of the tip of the spleen from the left costal margin] or the appearance of a newly palpable splenomegaly, development of at leat one of three constitutional symptoms: >10% weight loss in 6 months, night sweats, unexplained fever (>37.5°C).</li></ul></li></ul><!-- end field ca810c2d-3b72-4e89-b35d-dec2e2479a36 --><!-- end item 94a22469-6340-4789-9080-0a23acb967c5 -->","subChapters":[{"id":"3647d5c3-8140-5db6-ba12-ec26f7298fa0","slug":"basis-for-recommendation-b83","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 68da13a6-f0ac-4299-9383-58bc87306338 --><h4>Basis for recommendation</h4><!-- end field 68da13a6-f0ac-4299-9383-58bc87306338 -->","summary":null,"htmlStringContent":"<!-- begin item b83fdf74-9352-47c4-9c51-11629e7bc1ab --><!-- begin field 782bdb74-f687-4466-adae-9dabac27e79b --><p>The information on management of erythrocytosis and polycythaemia vera is based on expert opinion in the Oxfordshire Clinical Commissioning Group Referral Guidelines- <em>Polycythaemia</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycythaemia-erythrocytosis/references/\">Oxfordshire Clinical Commissioning Group, 2012</a>], the BMJ Best Practice guideline <em>Polycythaemia vera</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycythaemia-erythrocytosis/references/\">BMJ Best pracrice, 2016</a>]  and the British Medical Journal (BMJ) review article <em>The diagnosis and management of erythrocytosis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycythaemia-erythrocytosis/references/\">Keohane et al, 2013</a>].</p><h5>Management of erythrocytosis and iron deficiency</h5><ul><li>The recommendations to use iron replacement therapy judiciously is based on expert clinical experience that correcting iron deficiency in people with erythrocytosis can result in a rapid rise in the haematocrit increasing the risk of thrombosis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycythaemia-erythrocytosis/references/\">McMullin et al, 2005</a>].</li></ul><h5>Annual follow-up of people with polycythaemia vera</h5><ul><li>The recommendation that annual follow-up of people with polycythaemia vera can take place in primary care is based on expert opinion in the Oxfordshire Clinical Commissioning Group Referral Guidelines- <em>Polycythaemia</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycythaemia-erythrocytosis/references/\">Oxfordshire Clinical Commissioning Group, 2012</a>]. In practice, whether follow-up occurs in primary or secondary care is likely to be directed by the haematologist and will depend on local protocols. The information on signs and symptoms of myelofibrosis is derived from the BMJ Best Practice guideline <em>Polycythaemia vera</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycythaemia-erythrocytosis/references/\">BMJ Best pracrice, 2016</a>].</li></ul><!-- end field 782bdb74-f687-4466-adae-9dabac27e79b --><!-- end item b83fdf74-9352-47c4-9c51-11629e7bc1ab -->","subChapters":[]}]},{"id":"baf1cead-0613-5172-96fd-53be970cf149","slug":"secondary-care-treatment-of-polycythaemia-vera","fullItemName":"Secondary care treatment of polycythaemia vera","depth":3,"htmlHeader":"<!-- begin field e54a8cc5-0459-496e-8349-9b89d74b7882 --><h3>How is polycythaemia vera treated in secondary care?</h3><!-- end field e54a8cc5-0459-496e-8349-9b89d74b7882 -->","summary":null,"htmlStringContent":"<!-- begin item 86d14c3b-8475-45dd-9102-e55ed3adbe7a --><!-- begin field 9bec9d22-b3cb-4de5-bb9b-26c1aace015f --><ul><li><strong>The recommended management of all people with polycythaemia vera in secondary care includes:</strong><ul><li><strong>Venesection </strong>to maintain the haematocrit at less than 0.45.</li><li><strong>Prescription of aspirin 75 mg daily </strong>(unless this is contraindicated).</li></ul></li><li>I<strong>n addition, pharmacological cytoreductive therapy is recommended for people at high risk of thrombosis </strong>(people over the age of 60 years, or those with any history of thrombosis)<strong>. </strong>The first-line drug is usually hydroxycarbamide, with interferon alfa or ruxolitinib as possible alternatives where hydroxycarbamide is contraindicated, not tolerated, or ineffective.</li><li>P<strong>harmacological cytoreductive therapy may also be considered </strong><strong>if:</strong><ul><li>The platelet count is abnormally high.</li><li>There is evidence of disease progression, such as weight loss or night sweats.</li><li>Splenomegaly progresses or becomes symptomatic.</li><li>The person is poorly tolerant of venesection.</li></ul></li></ul><!-- end field 9bec9d22-b3cb-4de5-bb9b-26c1aace015f --><!-- end item 86d14c3b-8475-45dd-9102-e55ed3adbe7a -->","subChapters":[{"id":"dd2586ff-69aa-5e15-b4b7-d4da26db8379","slug":"basis-for-recommendation-57c","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 9d0969cf-72dc-40f4-8520-b5d275742b63 --><h4>Basis for recommendation</h4><!-- end field 9d0969cf-72dc-40f4-8520-b5d275742b63 -->","summary":null,"htmlStringContent":"<!-- begin item 57c4d46f-6400-4dcc-b85e-01ad56f90a00 --><!-- begin field b0b6a834-461f-4a02-a63a-54ea6a35a5e7 --><p>The information on secondary care treatment of polycythaemia vera is based on expert opinion in the British Society for Haematology <em>Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycythaemia-erythrocytosis/references/\">McMullin et al, 2005</a>], and the  BMJ Best Practice guideline <em>Polycythaemia vera</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycythaemia-erythrocytosis/references/\">BMJ Best pracrice, 2016</a>].</p><!-- end field b0b6a834-461f-4a02-a63a-54ea6a35a5e7 --><!-- end item 57c4d46f-6400-4dcc-b85e-01ad56f90a00 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}